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Abstract Genetic testing usually helps physicians to
determine possible genetic diseases in unborn babies,
genetic disorders of patients and the carriers who might
pass the mutant gene on to their children. They are
performed on blood, tissues or other body fluids. In recent
years, the screening tests and diagnostic tests have
improved quickly and, as a result, the risks of pregnancy
can be determined more commonly and physicians can
diagnose several genetic disorders in the prenatal period.
Detecting the abnormalities in utero enables correct
management of the pregnancy, prenatal and postnatal
medical care, and it is also important for making well
informed decisions about continuing or terminating a
pregnancy. Besides the improvements of conventional
invasive diagnostic tests, the discovery of circulating
cell-free foetal nucleic acids in maternal plasma has
developed a new point of view for non-invasive prenatal
diagnosis recently.
Keywords Prenatal diagnosis . Prenatal screening tests .
Common genetic disorders . Genetic counselling .
Prediction . Prevention and personalised medicine . PPPM
early in life
Introduction
Genetic testing usually helps physicians to determine
possible genetic diseases in both the prenatal and postnatal
periods. The main purposes are: to find out the genetic
disorders of the patients, the carriers who might pass the
mutant gene on to their children, the genetic diseases in
adults before they cause symptoms and to confirm the
clinical diagnosis in a patient who has symptoms.
Sometimes a disease can be prevented or treated if a
mutant gene is detected. Sometimes there is no treatment,
but the test results might help a person to make life
decisions, such as giving up smoking and keeping in
training. Genetic tests can be divided into two main
groups: prenatal and postnatal. Substantially, there is not
much difference between them. After obtaining the
material that will be used in genetic diagnosis, the
postnatal and prenatal procedures progresses are same.
Genetic diseases can be divided into four main groups:
single-gene disorders, chromosomal disorders, multifactorial
disorders and mitochondrial disorders.
1. Single-gene disorders, also called Mendelian or
monogenic, are a type that are caused by changes
or mutations in the DNA sequence of one gene.
Examples include cystic fibrosis, sickle cell anemia,
Marfan syndrome and Huntington’s disease.
2. Chromosomal disorders include numerical and
structural anomalies. Chromosomes are distinct
structures made up of DNA and protein which
carry genetic material. Abnormalities such as
missing or extra copies or gross breaks and
rejoinings (translocations) effect the genome and
so can result in diseases.
3. Multifactorial disorders, also called as complex or
polygenic, are a type that are caused by a combination
of environmental factors and mutations in multiple
genes. Examples include Alzheimer’s disease, diabetes
mellitus and cancer.
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4. Mitochondrial disorders are caused by mutations in
the nonchromosomal DNA of mitochondria. The
disorders that related with this type are rare and
examples include Kearns-Sayre syndrome, myoclonus
epilepsy with ragged red fibres, and mitochondrial
encephalomyopathy with lactic acidosis and stroke-like
episodes (MELAS).
What is a syndrome?
A syndrome is a group of multiple anomalies that has
more than one identifying feature and due to a single
known causative factor [1]. A syndrome also means that
there is a specific, recognisable pattern of abnormalities
according to each causative factor. The aetiological factor
could be a mutant gene, chromosomal abnormality or an
environmental factor, such as a teratogenic drug or
addictive substance. However there are still many situations
where the aetiology has not been understood [2]. The
population risk of having a child with a minor congenital
abnormality is estimated to be nearly 14% (skin tags,
dimples, etc.). However, around 2-3% of newborns have a
single major malformation, like cleft lip and palate or spina
bifida, that will require extensive medical treatment. Under
1% of newborns have multiple serious malformations,
including syndromes. However, the real occurrence of
malformations is much higher than estimations, but many
of them are aborted spontaneously, especially during the first
trimester of pregnancy [3].
Prenatal diagnosis
In the recent years, imaging techniques have improved fast,
as well as cytogenetic and molecular biology methods, and
maternal serum markers analyses have become routine, so
pregnant women with a high risk of having a baby with
anomalies can be determined more commonly and enable
the prenatal diagnosis of several congenital structural
malformations and genetic disorders. The aim of all the
prenatal diagnosis procedures is to detect birth defects
such as chromosome abnormalities, genetic syndromes
and other conditions in a foetus in utero. Detecting the
abnormalities in utero allows us to make correct
management of the pregnancy, prenatal and postnatal
medical care and treatment, and also it is important for
making informed decisions about continuing or terminating
the pregnancy [4].
Prenatal tests can be divided into two groups:
screening tests and diagnostic tests. Screening tests for
congenital anomalies include maternal serum marker
screening and ultrasound examination. Diagnostic testing
includes invasive prenatal diagnosis techniques and
foetal molecular analysis procedures without the need
of invasive techniques (Table 1). Diagnostic methods like
amniocentesis allow a specific diagnosis of chromosomal
abnormality and also allow us to confirm single-gene
syndromes that are suspected on prenatal ultrasonography
by biochemical, molecular or cytomolecular techniques
[5].
Screening tests
The traditional suggestion of quite a few of centres is that
all pregnant women aged 35 years or older should be
offered invasive prenatal testing [6]. However, maternal age
alone is a relatively inadequate predictor of prenatal
diagnosis. Down syndrome is more likely to occur at an
older maternal age and the risk of having a baby with
Down syndrome increases greatly after 35 years of age.
Additional screening methods, such as maternal serum
marker screening, should be included so the estimation
of the risk will be more appropriate.
The first trimester screening involves PAPP-A (pregnancy
associated plasma protein A) and free HCG (human chorionic
gonadotropin) levels in the maternal serum. These are
combined with ultrasound examination, especially with
nuchal translucency thickness and absence and/or presence
of the nasal bone. The detection rate of these methods is about
85-90% in regard to trisomy 21 and 18, with a false-positive
rate of 5%. In recent years, a new biochemical marker,
ADAM-12 (a disintegrin and metalloprotease-12) is added to
the first trimester screening. The combination of ADAM-12,
PAPP-A, HCG and NT measurements increases the detection
rate to 97% with a false-positive rate of 1% [4].
Table 1 Prenatal tests




• Routine obstetric ultrasound scan
• Targeted ultrasound scan
• Doppler studies
• Foetal echocardiography
Magnetic resonance imaging (MRI)
Diagnostic tests Invasive prenatal diagnosis techniques
• Chorion villus sampling
• Amniocentesis
• Cordocentesis
New approaches: foetal molecular analysis
procedures without the need of invasive
techniques
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In the second trimester, triple screening is mostly used
and it includes maternal serum α-fetoprotein (MSAFP),
unconjugated estriol and human chorionic gonadotropin
(hCG) [7]. The detection rate of this combination of
markers is approximately 60% in regard to trisomy 21,
with a false-positive rate of approximately 4% [8]. Maternal
urine human chorionic gonadotrophin β-core fragment
(HCGβcf) is also a potential marker in urine screening
for foetal Down syndrome in the second trimester [9].
Measuring inhibin A in maternal serum, in combination
with measurements of alpha-fetoprotein and the β subunit
of human chorionic gonadotropin (quadruple screening),
can also be used for the detection of Down syndrome [10].
Diagnostic tests
Invasive prenatal diagnosis techniques have been applied
for more than 20 years as a reliable method for couples with
various risk factors [5]. In the recent years, ultrasonography
techniques have improved fast and the maternal serum
marker analyses have become routine, so those pregnant
with a high risk can be determined more readily. Also, the
invasive prenatal diagnostic methods are using more
frequently in order to diagnose such risky cases effectively
and early [11].
The main prenatal diagnostic methods are chorion villus
sampling, amniocentesis and cordocentesis. Chorion villus
sampling and cordocentesis require more experience and
the complication rates and foetal loss rates are higher than
amniocentesis [12, 13]. While offering invasive diagnostic
techniques to a pregnant woman, the risk factors and
indications must be determined carefully. The main risk
factors when identifying cases are: advanced maternal
age, abnormal screening markers in the maternal serum,
abnormal ultrasonography findings, and previous history
of a foetus/child with chromosomal abnormalities or
congenital anomalies, as mentioned in the previous
article [14].
Methods of invasive prenatal cytogenetic diagnosis
The incidence of chromosomal disorders is about 0.5% in
live newborns [15, 16]. Chorionic villus, amniocytes or
umbilical blood cell sampling during pregnancy provide
reliable methods for performing prenatal diagnoses. In
some European countries more than 10% of the pregnant
population undergoes invasive prenatal testing [17].
Prenatal sampling criteria were as follows:
– Advanced maternal age (greater than or equal to 35 years)
– Abnormal screening markers
– Abnormal ultrasound findings
– Previous history of a foetus/child with chromosomal
abnormalities or congenital anomalies
– Family history of chromosomal abnormalities or
congenital anomalies
– Carrier of X-linked recessive disorders
– Patient anxiety
Chorionic villus sampling
Chorion villus sampling is used routinely as a first-trimester
diagnostic procedure for foetal genetic disease. Chorion
villus sampling had become widely used worldwide by the
early 1980s.
The procedure is generally done late in the first trimester,
most often between the 10th and 12th weeks. Use as early
as 8 weeks in special circumstances has been described.
About 8–10 mg (wet weight) chorion villus samples were
obtained transabdominally. A sample of the developing
placenta (trophoblast cells) is obtained for analysis. There
are two approaches to chorion villus sampling: trans-
abdominal and transcervical. Both methods are efficacious,
and the choice is in most cases dependent upon physician
preference. Transcervical chorion villus sampling has a
higher incidence of spontaneous pregnancy loss, but it is
the preferred method if the placenta is posterior or if the
bowel inhibits a transabdominal approach [18]. These
procedures should be performed under continuous ultra-
sound monitoring, by ‘freehand’ technique or using a
needle-guide attached to the ultrasound probe. Chorion
villus sampling is a technically more difficult procedure to
perform than amniocentesis, and it has been suggested that
100–400 chorion villus samplings are needed before the
learning curve reaches a plateau. With appropriate technical
equipment, an operator with sufficient practical experience
may decide on the sampling method in each case. In a UK
survey, 98% used the transabdominal approach [19]. The
main advantage of chorion villus sampling is early and
definitive chromosomal analysis [20]. One study reported a
0.8% greater loss rate with chorion villus sampling than
with amniocentesis, and a cytogenetic diagnosis rate of
97.8% [21]. Apart from a risk of miscarriage, there is a risk
of infection and amniotic fluid leakage. Chorion villus
sampling, on the other hand, has been linked to limb
reduction defects, although the evidence remains
conflicting. After 10 weeks there was no increased risk of
limb reduction defects, while the evidence below 10 weeks
of gestation is less substantial [22]. Placental mosaicism
and contamination by maternal tissue can be seen [23].
Mosaicism is detected in approximately 1% of chorion
villus samples. True chromosomal mosaicism is when two
or more abnormal cells lines are detected in two or more
culture flasks from the same individual.
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Amniocentesis
Amniocentesis remains the most common invasive
prenatal diagnostic procedure today. Amniocentesis was
first introduced into obstetric practice as a means of
detecting the severity of rhesus (Rh) isoimmunisation
about 50 years ago [24]. Amniocentesis was first
introduced for foetal sex determination by Serr et al.,
Fuchs and Riis in the 1950s [25, 26]. In 1983, Jeanty
reported a technique of amniocentesis “under ultrasound
vision” [27]. Amniocentesis for genetic diagnosis is typically
performed between 16 and 18 weeks’ gestation, which is
when the procedure is safest. However, it can be performed
from 14 to 20 weeks. Early amniocentesis is defined as
amniocentesis performed between 9 and 14 weeks. The
application of amniocentesis in the earlier weeks leads the
higher pregnancy loss rates [28]. Traditionally, the indications
for both chorion villus sampling and amniocentesis have
been very similar, with advanced maternal age being the
principal one. Advanced maternal age used to be the most
common indication for invasive prenatal diagnosis. Other
indications include an abnormal screening markers, abnor-
mal ultrasound findings and a previous pregnancy with a
chromosomal abnormality.
During amniocentesis, a needle (20–25 G) is inserted
into the amniotic sac using ultrasound guidance, and about
20 ml amniotic fluid is aspirated. Local anaesthesia is not
necessary. Foetal viability should always be checked before
and after the procedure. If the patient is Rh-negative, then
250 IU of anti-D immunoglobulin should be administered.
The major risk of this procedure is miscarriage, which is
estimated at 0.5-1% [17, 18]. The other risks are maternal
infection, injuries of foetus, preterm delivery and transient
amniotic fluid leakage [23]. Long-term complications
include respiratory distress and isoimmunisation. Karyotype
analysis of cells by culture is usually available in more
than 2 weeks’ time.
Cordocentesis: foetal blood sample
Cordocentesis seems to be a widely accepted method for
prenatal diagnosis.
Cordocentesis is a diagnostic genetic test that examines
blood from the foetal umbilical cord to detect foetal
abnormalities. This method is performed no earlier than
17 weeks into pregnancy and is usually performed at
20 weeks of gestation or later by obtaining 0.5-1 ml foetal
blood from the umbilical vein. The major risks of this
procedure are miscarriage, foetal death, premature birth,
bleeding and foetal bradycardia [29]. Cordocentesis
requires more experience and foetal loss rate is high [12,
13]. Foetal loss is the primary risk associated with
cordocentesis and occurs in 1-2% of procedures. However,
when quick results are required, cordocentesis can be
performed, since it is highly safe, with a low complication
frequency. In addition, infection, blood loss at the puncture
site and premature rupture of membranes give risks similar
to amniocentesis. For cytogenetic analysis, 0.5–1 ml foetal
blood was taken using a heparinised syringe. Cordocentesis
testing has a turnaround time of about 72 h and can detect
chromosomal abnormalities.
New approaches: foetal molecular analysis procedures
without the need for invasive techniques
Besides these invasive diagnostic tests, in the recent years
the discovery of circulating cell-free foetal nucleic acids in
maternal plasma has developed a new point of a view for
non-invasive prenatal diagnosis. These new approaches
have been based mainly on the detection of foetal nucleated
cells in maternal blood, the isolation of foetal trophoblastic
cellular elements shed into the uterine cavity and the
endocervical canal, and the analysis of foetal genetic
material present in maternal plasma [30, 31].
Invasive procedures have certain risks associated with
them. On the other hand, non-invasive prenatal diagnosis
gives ability to obtain the necessary genetic information
from the foetus.
The first study on the cell-free foetal DNA (ffDNA) in
maternal blood as a marker for non-invasive prenatal
diagnostics aimed to detect sequences of the Y-chromosome
as a marker of the male foetus in the blood of pregnant
women to sex-linked prenatal diagnosis [32]. The
sensitivity of Y-chromosome loci by the 7th week of
gestation by standard polymerase chain reaction (PCR)
was 95%; while using real-time PCR, the sex of an
embryo can be determined at the 5th week of development
with 100% accuracy. In the presence of male foetal cells
among 12,800 cells of the mother can indicate a positive
result.
Lo and colleagues described the use of ffDNA to
detect the RHD gene in RhD-negative pregnant women
[33]. Li et al. [34] carried out investigations to identify the
Rh antigen, Rh-D foetal blood in Rh-negative women,
which form a risk group. The detection of such a condition
could result in activities as early as possible towards the
prevention of Rh conflict between mother and foetus.
The technique used by Hyland et al. [35] can detect
ffDNA in maternal plasma by real-time PCR. Cell-free
foetal DNA involves about 4–6% of all cell-free DNA in
the maternal circulation [33]. Internal controls are used to
confirm the presence of foetal DNA to minimise false-
negative results and to reliably determine foetal DNA as
early as 7 weeks after conception. Since only male foetuses
could be detected by the SRY gene, Hyland and colleagues
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also utilised the RASSF1A gene to confirm the presence of
foetal DNA from female fetuses [35]. By determining the
foetal RHD status, they could predict with 100% accuracy
compared with the infant’s serotype, determined from cord
blood after delivery. In rare cases, they failed to determine
foetal status. The ffDNA can be applied more broadly in
determination of foetal RHD status. The timely identifica-
tion of foetal chromosomal anomalies is an important
function of prenatal diagnosis [36]. The level of ffDNA in
maternal plasma and serum increased on average twofold
when a foetus had Down syndrome. Cell-free foetal DNA
in other aneuploidies has changing levels. For example,
in the case of trisomy of chromosome 13 it is increased,
but remained low in trisomy 18. Pathology of the
placenta is given as a possible reason for changing the
concentration of ffDNA during the development of a
fetus with abnormal karyotype.
Interphase fluorescence in situ hybridisation (FISH)
analysis of floating maternal blood cells can identify foetal
trisomy of chromosomes 21, 18, X, and Klinefelter
syndrome (47, XXY) [37–39]. Thus, the study of 42,312
nuclei of cells isolated from 40 women’s blood, for the
purpose of prenatal diagnosis at different stages of
pregnancy (10–27 weeks), allowed the detection of Down
syndrome in two cases, which were later confirmed by
amniocentesis [39]. The genders of all foetuses with
karyotype 46, XX, and five of the 16 foetuses with male
karyotype were accurately identified. However, in one case
it failed to detect a foetus with Edwards’ syndrome of
aberrant cells among 640 sorted cells. In other observations,
chromosomal abnormalities of the foetus were missing
according to FISH and subsequent karyotyping amniocytes.
Only single cases of prenatal diagnosis of aneuploidy were
reported in most publications. This test has yet to lower the
sensitivity and specificity compared with those of
invasive techniques. The main problem remains as the
low concentration of foetal cells in the enriched fraction,
which does not react with DNA hybridisation probes.
Therefore, a limited number of cells was analysed, which
increases the probability of error. There were certain
difficulties in determining the sex of the fetus. In a study
of the DNA of sorted cells by PCR amplification of Y-specific
sequences, foetal sex at 8-19 weeks of pregnancy was
identified in 94-100% of cases [40]. This approach is not
superior to existing screening tests since it is still considered
as experimental and informative. Significant complexity and
high cost of sorting foetal cells prevents its use in clinical
practice as a screening for aneuploidy.
Although newer techniques such asmethylation-dependent
PCR and digital PCR offer promise, the non-invasive
diagnosis of Down syndrome and other aneuploidies still
remains challenging [41]. The novel molecular markers for
the detection of chromosomal imbalances in the foetus, as
well as successful experiments carried out to detect foetal
single nucleotide polymorphisms and point mutations, are
currently being investigated in addition to measuring the
concentration of ffDNA in maternal blood. There are
some studies indicating non-invasive prenatal diagnosis
of Huntington’s disease [42], cystic fibrosis [43] and other
conditions. The detection of the SRY gene leads to the
determination of foetal sex in women at risk of carrying a
foetus with an X-linked condition [44].
Compared with a group of women with normally
proceeding pregnancies, a nearly fivefold increase in ffDNA
was reported in the blood of mothers with pre-eclampsia [45].
Further pathological examination revealed not only an
increase in the concentration of cell-free DNA of the foetus,
but also a significant increase in cell-free DNA of the
mother, for which an increase in both figures indicates
the severity of the disease. In addition, the concentration
of cell-free DNA of the foetus increased long before the
first clinical symptoms. An increased concentration of
foetal DNA may be the result of necrosis and apoptosis
of the placenta, since the plasma DNA is a marker of cell
death. A problem of renal and hepatic function observed
with pre-eclampsia decreases the excretion of circulating
DNA from maternal blood.
Increasing the concentration of ffDNA in maternal blood
is seen in other disorders of pregnancy, such as spontaneous
miscarriage in the first trimester, pre-term labour [46], and
the true increment of the placenta [47].
It is possible to determine the karyotype of foetal cells
circulating in the mother’s bloodstream. In late pregnancy,
one foetal erythroblast corresponds to 10,000 maternal
nucleated cells. With the help of modern immunofluorescent
or magnetic modules for flow cell sorting (FACS, MACS,
and others), the fraction of foetal cells can reach 10%
[37]. To isolate erythroblasts, fluorochrome-labelled or iron
particles with monoclonal antibodies to proteins [membrane
proteins—transferrin receptor (CD71), glycophorin a
receptor and thrombospondin] are used [38]. First, blood
cells are centrifuged in a triple density gradient, and in
some cases, are carried out by means of nuclear dyes in
selection of cells containing a nucleus. The negative
sorting of CD45-positive lymphocytes is also recommended.
In addition to erythroid cells in maternal blood, there are foetal
lymphocytes and granulocytes, as well as trophoblastic cells,
but they are inappropriate for cytogenetic studies [37, 38].
The determination of foetal RHD status is becoming
available as a clinical tool, and is likely to be the first of many
applications of non-invasive prenatal testing in the future.
Modern technologies permit the use the new knowledge
into practical medicine. Further study of nucleic acids in
maternal blood is necessary in order to develop new markers
for non-invasive prenatal diagnosis of pathological conditions
of the foetus at an early stage of their occurrence.
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It would not be possible here to mention all the
syndromes that can determined by prenatal diagnosis. The
followings are the syndromes that we usually experience in
the clinic and while giving genetic counseling and also we
mentioned the common syndromes that we come across at
the postnatal diagnosis.
Down syndrome (trisomy 21)
Trisomy 21 is the most common chromosomal abnormality
in humans. Approximately 0.45% of human conceptions
are trisomic for chromosome 21 (Fig. 1) [48]. The
frequency of trisomy 21 in the population is 1 in
700–1,000 of live births [49]. Characteristic facial
features and hypotonia are present in almost all
patients; approximately 50% suffer from congenital
cardiac anomalies [50]. The features of this syndrome
include mental retardation, retarded growth, flat hypo-
plastic face, epicanthic skin folds, low-set ears with
prominent antihelix, thickened tongue, laxness of joint
ligaments, pelvic dysplasia, broad hands and feet, single
palmar crease, lenticular opacities and heart disease
(Fig. 2).
Edwards’ syndrome (trisomy 18)
Trisomy 18 is the second most common autosomal
trisomy after Down syndrome. This syndrome charac-
terised by severe psychomotor and growth retardation,
microcephaly, microphthalmia, micrognathia, cardiac
and urogenital anomalies (Figs. 3, 4). The prevalence
is approximately 1 in 3,000–8,000 [51]. The risk of
trisomy 18 is known to increase as the age of the child’s
mother at the time of pregnancy increases [52]. The risk
of trisomy 18 is also associated with increasing
paternal age.
Fig. 1 Karyotype of a patient with trisomy 21
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Patau syndrome (trisomy 13)
The trisomy 13 syndrome typically includes central
nervous system malformations, (holoprosencephaly and
arinencephaly) with consequent severe psychomotor
dysfunction and convulsions. This syndrome is characterised
by defects of eye (microphthalmia), polydactyly, cleft lip,
scalp skin defect and cardiac defects. The incidence is
approximately 1 in 5,000 births. It is the third most frequent
trisomy among live births [53].
Turner syndrome (monosomy X)
Turner syndrome is the result of total or partial monosomy
of the X-chromosome (Fig. 5). This syndrome is charac-
terised by short stature and gonadal failure. Other com-
monly reported features include lymphedema, renal
anomalies, cardiac defects, webbed neck, and low posterior
hairline. The birth prevalence of Turner syndrome has been
estimated to be from 1 in 2,000 to 1 in 5,000 female live
births.
Prenatal diagnosis of Down syndrome, Edwards
syndrome, Patau syndrome and Turner syndrome
The majority of chromosome abnormalities identified in
prenatal samples are trisomy for chromosomes 13, 18, 21
and sex chromosome aneuploidies (Patau, Edwards and
Down syndromes, and the less severe Turner and
Klinefelter syndromes). Trisomy 21 is the predominant
reason for pregnant women who underwent prenatal
diagnosis [54, 55].
In recent years, first-trimester screening programmes
have been developed and recent studies concluded that
the sensitivity of first trimester screening (11–14 weeks)
is much higher than second trimester tests (Table 2)
[56]. PAPP-A and human chorionic gonadotropin combi-
nation has a detection rate of 60–65% for trisomy 21 [57].
According to another study in the first trimester,
screening by a combination of ultrasound markers and
maternal serum β-hCG and PAPP-A can identify up to
97% of foetuses with trisomy 21 and other major
chromosomal abnormalities [58]. About 75% of trisomy
21 foetuses have increased nuchal translucency thickness,
70% have absent nasal bone and 25% have maxillary
hypoplasia [59].
The risk for many of the chromosomal defects increases
with maternal age. As in recent years maternal age has
increased into middle age, the frequency of chromosomal
abnormalities increases. A maternal age of 35 years at
delivery has been the medicolegal standard in the USA and
Europe for more than 20 years and this high risk group
constituted 5% of the pregnant population [60].
Turner syndrome may be diagnosed or suspected
prenatally because of ultrasonographic evidence of cystic
hygroma, oedema, and non-immune hydrops. Ultrasonogra-
phy showing a cardiac defect (coarctation of aorta), intra-
uterine growth retardation, renal anomalies (horseshoe kid-
Fig. 2 The craniofacial apperance of a patient with trisomy 21
Fig. 3 The craniofacial apperance of a patient with trisomy 18
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ney) or short limbs also may suggest Turner syndrome.
Besides ultrasonographic evidence, the maternal serum
AFP and uE3 concentrations were slightly reduced in
pregnancies affected with Turner syndrome as has been
reported previously. So, women with an increased risk
of Down syndrome, based on maternal serum marker
screening, should be informed that Turner syndrome
may be a possibility, even in the absence of ultrasono-
graphic findings [61]. If an abnormality associated with
Turner syndrome is diagnosed by ultrasonography or if
multiple marker screening is positive, the recommended
follow-up is invasive prenatal diagnostic techniques for
foetal karyotyping [62] (Table 3).
DiGeorge syndrome
DiGeorge syndrome is one of the most common microdeletion
syndromes. It is characterised by hypoplasia or aplasia of
the thymus and parathyroid glands, a conotruncal heart
defect (tetralogy of Fallot, type B interrupted aortic
arch, truncus arteriosus, right aortic arch and aberrant
right subclavian artery) and various craniofacial dys-
morphism. It is the second most frequent chromosomal
abnormality associated with congenital heart defects.
The estimated incidence of the submicroscopic deletion
of chromosome 22q11 is 1 in 4,000 live births [63, 64].
This syndrome is caused by the developmental defect of
the third and fourth pharyngeal pouches [65]. The
submicroscopic deletion of chromosome 22 that is
detected by FISH is frequently associated with the
syndrome.
Prenatal diagnosis of a 22q11 deletion was reported in a
foetus with a known affected sister and father [66], in the
foetus of a patient with the deletion and veloocardiofacial
syndrome [64] in the foetus of a mother with congenital
heart disease [67], and in a foetus with interrupted aortic
arch type B [68]. Thus, with ultrasonographic evidence and/
Fig. 4 Karyotype of a patient with trisomy 18
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or familial history, prenatal diagnosis of Di George
syndrome is possible with FISH.
Fragile X syndrome
Fragile X syndrome (FXS) is the leading inherited
cause of intellectual disability, accounting for 40% of
all X-linked mental retardation [69]. The prevalence of
FXS is 1 in 4,000 males and 1 in 8,000 females. FXS
occurs in individuals with an FMR1 full mutation.
Postnatal and prenatal diagnosis is feasible by direct
DNA analysis. A new approach to prenatal diagnosis of
FXS in amniotic fluid cells is described, using a rapid and
simple antibody test on uncultured amniotic fluid cells
[70].
Prenatal diagnosis of the FXS can be performed either
on chorionic villi or amniotic fluid cells. In both tissues, a
direct DNA analysis (Southern blotting) of the mutation
responsible for the FXS is carried out [71, 72].
Cystic fibrosis
Cystic fibrosis (CF) affects epithelia of the respiratory
tract, exocrine pancreas, intestine, male genital tract,
hepatobiliary system, and exocrine sweat glands, resulting
in complex multisystem disease. CF is caused by
mutations in the gene encoding CF transmembrane
conductance regulator [73]. The incidence of CF varyies
from 1 in 2,500 to 1 in 5,000 (carrier rate 1 in 25–35) [74].
The disease may be revealed by foetal bowel hyper-
echogenicity during routine ultrasonography in the
second trimester of pregnancy. However, foetal bowel
hyperechogenicity is not specific for CF. The potential of
hyperechogenic foetal bowel to act as a hallmark for
prenatal CF screening in the general population is
controversial [75]. Diagnostic investigations are based
on screening for CF-causing mutations, foetal karyotyp-
ing, and screening for infections. To date, almost 900
mutations have been described throughout the CFTR
gene, but very few deletions have been identified [76].
Fig. 5 Karyotype of a patient with Turner syndrome
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Conventional PCR-based methods usually detect deletions
only when they are present in the homozygous state.
Two relatively frequent large deletions have recently
been described: 3120+1kbdel8.6kb was found in 13% of
CF chromosomes in Israeli-Arab patients [77], and
CFTRdele2,3 (21 kb) accounts for 1–6.4% of CF
chromosomes in Slavic populations [78]. Screening for
cystic fibrosis should be offered to families in which
foetal hyperechogenic bowel is diagnosed at routine
ultrasonography [75].
Williams syndrome
Williams syndrome (WS) is characterised by cardiovas-
cular disease (elastin arteriopathy, peripheral pulmonary
stenosis, supravalvular aortic stenosis, hypertension),
distinctive facies, connective tissue abnormalities, men-
tal retardation (usually mild), a specific cognitive
profile, unique personality characteristics, growth abnor-
malities, and endocrine abnormalities (hypercalcemia,
hypercalciuria, hypothyroidism, and early puberty). A
recent study of WS reported a prevalence of 1 in 7,500
[79]. Increased foetal nuchal translucency and low
maternal serum alpha-fetoprotein (MSAFP) can be
determined in prenatal screening. Also, foetal ultrasound
can reveal multicystic dysplastic kidney and congenital
heart defects [80]. The inheritance pattern of this
syndrome is autosomal dominant but most of the cases
are de novo occurrences. Prenatal testing is clinically
available and suitable for familial cases. FISH testing
may be used to detect the microdeletion at 7q11.23, a
region that includes approximately 17 genes (including
the elastin gene and LIM-kinase 1 gene) [81]. Chorionic
villus sampling or amniocentesis can be performed for
FISH analysis.
Table 2 Sensitivity of first-trimester screening programs, for a 5%
false positive rate. (Taken from [58])
Screening programme Sensitivity (%)




Maternal age+AFP+bhCG+inhibin A 70
Maternal age+AFP+bhCG+uE3+inhibin A 75
Maternal age+nuchal translucency 75
Maternal age+PAPP-A+free bhCG 65
Maternal age+PAPP-A+free bhC+nasal bone 93
Table 3 First and second trimester ultrasonographic findings of the


























Hypoplastic bladder + +























Dandy walker + +
Cleft lip, cleft palate + +
Micrognathia +








Thickened nuchal fold + + + +
16-18 week >5 mm
18-24 week>6 mm











Equinavarus deformity + +
Rocker-bottom feet +
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Achondroplasia
Achondroplasia is the most common type of human
dwarfism. The estimated incidence is between 1 in 10,000
and 1 in 30,000 live births [82–84]. The syndrome is
characterised mainly by disproportionately short stature,
macrocephaly, spinal stenosis, brachidactyly, and three
pronged fingers (trident) [85]. The syndrome has an
autosomal inheritance pattern, but more than 90% of the
cases represent a fresh gene mutation and these cases are
strongly associated with increased paternal age. Muta-
tions in the gene encoding fibroblast growth factor
receptor 3 (FGFR3) have been found as a causative
factor. The prenatal ultrasonography allows the detection
of skeletal dysplasias, but most of them appear in the
second trimester or later [85]. In prenatal ultrasound,
micromelia is the most predominant finding. The frontal
bossing and depressed nasal bridge can also be recognised
(Figs. 3, 4). Occasionally more subtle anomalies, such as
the trident hand (an increased space between the third and
fourth digit), can be observed (Figs. 3, 4). Besides these, a
ratio of femur length to abdominal circumference of <0.16
with a hypoplastic thorax can be used as indicative of a
skeletal dysplasias [86]. Chorionic villus sampling or
amniocentesis can also be performed with pregnancies at
risk for FGFR3 mutation, and a non-invasive method
using maternal plasma and quantitative fluorescent PCR
(QF-PCR) may be useful for the diagnosis of the foetal
achondroplasia. Lim et al. [87] used circulating foetal
DNA (cf-DNA) in maternal plasma, and they mentioned
the QF-PCR method is suitable for detection of the
FGFR3 mutation (G1138A) causing achondroplasia.
Osteogenesis imperfecta
Osteogenesis imperfecta is a heterogeneous group of
genetic disorders characterised by severe bone fragility,
abnormal ossification and multiple fractures. The incidence
in the population is nearly 1 in 10,000 and is maintained by
a high rate of new mutations [88, 89]. The phenotype of the
patients results from mutations in either of the two genes,
COLlAl and COL1A2. These genes encode collagen 1,
which is an important structural protein in bone [90]. The
early prenatal diagnosis of lethal skeletal dysplasias is
possible with the guidance of ultrasonographic evidence
and/or familial history. In prenatal ultrasound examination
sonographic findings include broad, short fractured long
bones and significant decrease in bone ossification.
Conclusions and outlook
The development of the imaging techniques, as well as
cytogenetic and molecular biology methods with maternal
serum marker analyses, has opened up new opportunities in
genetic prenatal diagnosis for all pregnancies and especially
pregnancies at high risk of resulting in a baby with an
abnomality. Detecting the abnormalities in utero enables the
correct management of the pregnancy, prenatal and postna-
tal medical care and treatment, and also it is important for
making informed decisions about continuing or terminating
the pregnancy.
The main invasive prenatal diagnostic methods are
chorion villus sampling, amniocentesis and cordocentesis.
These standard methods are based on culturing foetal cells
and then implementing classical and molecular cytogenetic
techniques or molecular methods. Amniocentesis remains
to be the most common invasive prenatal diagnostic
procedure today [91], although the miscarriage risk is
estimated at 0.5-1% [92, 93]. The other risks are maternal
infection, injuries to the fetus and preterm delivery. Chorion
villus sampling and cordocentesis require more experience,
and the complication rates and foetal loss rates are higher
than amniocentesis [12, 13]. Besides these invasive
diagnostic tests, the discovery of circulating foetal DNA
in maternal plasma has developed a new point of a view for
non-invasive prenatal diagnosis. The main risk factors that
using when identifying cases at risk of having a baby with
chromosomal abnormality and/or genetic disorder and
Table 4 Top ten most common single-gene Mendelian disorders in
the UK and their frequency per 1,000 births. (Taken from [100])
Familial combined hyperlipidemia 5.0
Familial hypercholesterolemia 2.0
Dominant otosclerosis 1.0
Adult polycystic kidney disease 0.8
Multiple exostoses 0.5
Huntington’s disease 0.5
Fragile X syndrome 0.5
Neurofibromatosis 0.4
Cystic fibrosis 0.4
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suggesting the use of prenatal diagnosis methods are:
advanced maternal age, abnormal screening markers in
maternal serum, abnormal ultrasonography findings,
previous history of a foetus/child with chromosomal
abnormalities or congenital anomalies [94]. In most
countries, including Turkey, the suggestion is that all
pregnant women who are 35 years of age or older should
be offered invasive prenatal testing [3].
In conclusion, maternal screening tests are directive
and prenatal ultrasonography is capable of recognising
syndromic patterns of anomalies. Invasive prenatal tests
require experience and have various complications, but
we do not have enough experience in alternative prenatal
diagnostic tests, such as testing circulating cell-free foetal
nucleic acids in maternal plasma.
The majority of abnormalities identified in prenatal
samples are trisomy for chromosomes 13, 18, 21 and sex
chromosome aneuploidies. In some countries, especially
in Europe, the recommended diagnostic techniques
include rapid FISH, MLPA (multiple ligation PCR
amplification) and QF-PCR [4]. These methods have
some advantages. The small sample amount is sufficient
and the results are obtained in few days. Also, these
approaches include classical cytogenetic analysis when
there are suspicions for other chromosomal aberrations. In
Turkey, most of the laboratories perform rapid FISH,
MLPA and QF-PCR with standard methods that are based
on culturing foetal cells respectively in order to achieve
rapid pregnancy management and not to miss other
chromosomal aberrations.
All people have a risk of diseases due to genetic
mutations. A higher prevalence of genetic diseases in
particular communities may exist, however, due to some
social or cultural factors.
Generally, the incidence of chromosomal disorders
does not change according to the population. Nearly
0.5% of all newborns have a chromosomal abnormality
and 7% of all stillborns have a chromosomal abnormality
[95]. The main difference between the populations
involves the single-gene disorders, especially the autoso-
mal recessive ones, due to consanguineous marriages.
The rate of consanguineous marriage varies in relation to
various factors, such as race, characteristics of popula-
tion, religion and moral features in different countries
[96]. Gene frequency and genetic structure are changed by
this kind of marriage [97]. The results of many studies
show that the rate of consanguinity among parents of
children with rare recessive diseases is quite above
Turkey’s average [98]. Turkey has a high rate of
consanguineous marriages. Different studies indicate that
today 20-25% of marriages are consanguineous [98],
especially in the Eastern part of Turkey, where this rate
increases up to 34.4% [97].
There are no regular incidence studies for genetic
diseases in Turkey. The most common disorders are cyctic
fibrosis, beta-thalasemia, sickle cell anemia, spinal musculer
atrophy, infantile polycystic kidney disease, acondroplasia,
Duchenne/Becker musculer dystrophy, and haemophilia
A and B [99]. In the United Kingdom, incidence studies
related with genetic diseases revealed the most common
disorders as shown in Table 4 [100].
The ministry of health began to work on the studies
that deal with the prevention of the genetic diseases in
Turkey. The routine genetic diseases screening programmes
for newborns in Turkey include metabolic diseases such as
phenylketonuria, biotinidase deficiency and hypothyroidism,
and besides these diseases, prenatal screening programmes
have been applied for many years. Within the scope of
these studies, the health institutions and organisations are
applying various screening and diagnostic programmes
besides the medical and genetic counselling service in
order to prevent mentally and physically handicapped
children [101]. Besides these health politics, various
scientific work groups have been constituted within the
Ministry of Health [102].
As a result, the control of genetic diseases should be
based on an integrated and comprehensive strategy and it
is essential that the Health Ministry should instigate
collaborations to prevent genetic diseases. Intelligent
political regulation in the healthcare sector must be
arranged carefully and participation of the private sector
should be provided. Awareness of the public about the
basic principles of genetic diseases and genetic counselling
should be raised because screening programmes need to
be supported by public education. Also, the countries
that have a high rate of consanguineous marriages must
focus their attention on this subject besides autosomal
recessive diseases. In the near future, the granting of
“orphan” drug designation for the treatment of rare/orphan
diseases will encourage initiatives to promote the
development of appropriate drugs. This may provide
therapeutic benefits to the patients and also somatic-cell
gene therapy may play an important part in the
management of genetic diseases in the future [96].
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